Charles Zhu
Stock Analyst at Guggenheim
(2.41)
# 2,477
Out of 5,129 analysts
19
Total ratings
47.06%
Success rate
15.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $12.61 | -4.84% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $9.45 | +132.80% | 1 | Jun 18, 2025 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.72 | +597.67% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $103.15 | -45.71% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $6.48 | +239.51% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $37.20 | -30.11% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $31.90 | +0.31% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $22.83 | -38.68% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $12.61
Upside: -4.84%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $9.45
Upside: +132.80%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.72
Upside: +597.67%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $103.15
Upside: -45.71%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $6.48
Upside: +239.51%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $37.20
Upside: -30.11%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $31.90
Upside: +0.31%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $22.83
Upside: -38.68%